Benefits
NAD+ metabolome rose in the blood (a marker)
In one 7-day trial in healthy middle-aged adults, RiaGev raised the blood NAD+ metabolome, with NADP+ up 27 percent versus placebo. This is a blood marker, not a measured change in energy output, muscle function or aging. The trial did not compare RiaGev against nicotinamide alone or D-ribose alone, so there is no human evidence that the combination raises NAD+ more than its individual parts.
Simultaneous ATP and NAD+ restoration
The same 7-day trial reported increases in blood high-energy phosphates (a marker linked to ATP) alongside the NAD+ metabolome rise. These are blood markers measured over one week in healthy adults, not measurements of cellular work, exercise capacity or muscle performance, and no comparison against the single ingredients was done.
Mitochondrial bioenergetics optimization
NAD+ and ATP are both required for mitochondrial function, which is the rationale for combining nicotinamide and D-ribose. No trial has measured mitochondrial function, ATP production or physical performance after RiaGev in people, so this is a proposed mechanism rather than a demonstrated effect.
No aging or longevity outcome has been tested
NAD+ levels fall with age, which is the marketing rationale for NAD+ products. RiaGev has not been tested for any aging, longevity or age-related outcome. The one published trial ran 7 days and measured blood markers, glucose, cortisol and questionnaire fatigue in healthy adults.
Mechanism of action
Complementary NAD+ biosynthesis pathway engagement
Nicotinamide is converted to NMN by nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting salvage enzyme, and NMN is then adenylated by NMNAT enzymes to form NAD+. D-ribose feeds the pentose phosphate and purine pathways that supply the adenine nucleotide (ATP, ADP, AMP) pool. RiaGev does not contain nicotinamide riboside, so the NR kinase (NRK1/2) route described for NR does not apply here.
Dual energy pool restoration
Nicotinamide supplies substrate for the NAD+ pool through the NAMPT salvage pathway, while D-ribose supplies ribose for the adenine nucleotide pool (ATP, ADP, AMP). Whether supplying both together produces more benefit than either one alone has not been tested in people.
Sirtuin and PARP-1 co-activation support
With elevated NAD+, both sirtuins (SIRT1–7 deacylases governing longevity pathways) and PARP-1 (DNA repair) have adequate substrate. With replenished ATP, the cellular machinery downstream of sirtuin signaling (mitochondrial biogenesis, DNA repair synthesis, protein quality control) has the energy currency to actually execute these processes — completing the energy restoration loop.
Clinical trials
Randomized, crossover pharmacokinetic study comparing RiaGev® (NR + D-ribose complex) vs equivalent doses of NR alone and D-ribose alone on whole-blood NAD+. Note: full peer-reviewed publication for RiaGev®-specific PK trial may be limited; primary documentation through Bioenergy Life Science.
Per manufacturer.
RiaGev® produced greater whole-blood NAD+ elevation than equivalent NR dose alone. Critical caveat: as primarily manufacturer-published data, claims warrant independent peer-reviewed validation. The 'synergistic' framing relies on dose-equivalent comparisons that should be scrutinized.
Pilot study of the nicotinamide + D-ribose combination on the blood NAD+ metabolome and related markers in healthy middle-aged adults (not a fatigue-patient population). Industry-funded: authors are Bioenergy Life Science employees.
50 healthy middle-aged adults (ages 36–65). Randomized, triple-blind, placebo-controlled crossover; 1520 mg RiaGev® twice daily for 7 days vs placebo, 7-day washout between arms. Blood samples on days 1, 3, 5, and 8.
NAD+ metabolome significantly increased; NADP+ rose 27% vs placebo (p=0.033). Glutathione and high-energy phosphates also increased. Blood glucose significantly reduced (p=0.013) without changes in insulin secretion, suggesting improved insulin sensitivity. Salivary cortisol decreased (p=0.026). Subjects reported less fatigue, improved mental concentration, and improved motivation (CIS questionnaire). No adverse events. Established RiaGev® as safe and efficacious NAD+ enhancer in middle-aged adults.